Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin
Study’s first results presented at the international “Collaborative Workshop – Ivermectin against Covid-19” held on December 15, 16 and 17 at the initiative of MedinCell.
No side effects observed with the first two doses in the study, which includes a total of three doses.
A first long-acting injectable formulation is ready to enter regulatory development.
MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.